SYMLIN REMS Purpose
The purpose of the SYMLIN REMS program is to inform health care providers about the following serious risks of SYMLIN:
- Increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes
- Importance of insulin dose reduction
Counsel and instruct your patients on insulin dose reduction to minimize the risk of hypoglycemia.
- Proper patient selection. SYMLIN is contraindicated in patients with any of the following:
- Hypoglycemia unawareness
- Confirmed gastroparesis
- Serious hypersensitivity to SYMLIN or any of its product components
Please see the non promotional SYMLIN Factsheet, reviewed by the FDA, for more detailed safety information.